Fubotv earnings beat by $0.10, revenue topped estimates
Investing.com -- Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) shares surged 11.4% after the biopharmaceutical company reported second quarter earnings that exceeded analyst expectations and significantly raised its full-year revenue guidance, driven by strong sales of its ARCALYST therapy.
The company reported second quarter adjusted earnings per share of $0.23, beating analyst estimates of $0.19. Revenue reached $156.79 million, surpassing the consensus estimate of $145.28 million and representing a 44.4% increase compared to $108.6 million in the same quarter last year. The strong performance was primarily fueled by expanding ARCALYST penetration across the recurrent pericarditis patient population.
"Our robust commercial performance in the second quarter was driven by expanding ARCALYST penetration across the recurrent pericarditis population, supported by growth among both new and repeat prescribers," said Sanj K. Patel, Chairman and Chief Executive Officer of Kiniksa.
Following the impressive results, Kiniksa raised its 2025 ARCALYST net sales guidance to between $625 million and $640 million, up from its previous forecast of $590 million to $605 million. The new guidance midpoint of $632.5 million represents 52% YoY growth and exceeds the analyst consensus of $604 million.
Since launching ARCALYST, more than 3,475 prescribers have written prescriptions for recurrent pericarditis, with patients remaining on therapy for an average of approximately 30 months. The company noted that approximately 15% of the target 14,000 multiple-recurrence patients were actively on ARCALYST treatment as of the end of the second quarter.
Kiniksa reported a net income of $17.8 million for the quarter, compared to a net loss of $3.9 million in the second quarter of 2024. The company ended the quarter with $307.8 million in cash, cash equivalents, and short-term investments with no debt, and expects to remain cash flow positive on an annual basis.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.